References
- Blaker, H. ( 2000). Confidence curves and improved exact confidence intervals for discrete distributions. Canadian Journal of Statistics 28(4):783–798. URL https://doi.org/10.2307/3315916.
- Green, S. J., Dahlberg, S. ( 1992). Planned versus attained design in phase II clinical trials. Statistics in Medicine 11(7):853–862. URL http://view.ncbi.nlm.nih.gov/pubmed/1604065.
- Koon, H. B., Krown, S. E., Lee, J. Y., Honda, K., Rapisuwon, S., Wang, Z., Aboulafia, D., Reid, E. G., Rudek, M. A., Dezube, B. J., Noy, A. ( 2014). Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. Journal of Clinical Oncology 32(5):402–408. URL http://view.ncbi.nlm.nih.gov/pubmed/1604065.
- Koyama, T., Chen, H. ( 2008). Proper inference from Simon's two-stage designs. Statistics in Medicine 27(16):3145–3154. URL http://view.ncbi.nlm.nih.gov/pubmed/1604065.
- Li, Y., Mick, R., Heitjan, D. F. ( 2012). A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. Clinical Trials (London, England) 9(3):293–302, doi:10.1177/1740774512443429. URL https://doi.org/10.1177/1740774512443429.
- Noy, A., Scadden, D. T., Lee, J., Dezube, B. J., Aboulafia, D., Tulpule, A., Walmsley, S., Gill, P. ( 2005). Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team. Journal of Clinical Oncology 23(5):990–998, doi:10.1200/jco.2005.11.043. URL https://doi.org/10.1200/jco.2005.11.043.
- Shan, G. ( 2015). Exact Statistical Inferencefor Categorical Data. 1st ed. London, UK: Academic Press. URL http://www.worldcat.org/isbn/0081006810.
- Shan, G. ( 2016a). Exact confidence limits for the response rate in two-stage designs with over or under enrollment in the second stage. Statistical Methodsin Medical Research in press. Available at: https://doi.org/10.1177/0962280216650918.
- Shan, G. ( 2016b). Exact sample size determination for the ratio of two incidence rates under the Poisson distribution. Computational statistics 31(4):1633–1644, doi:10.1007/s00180-016-0654-6. URL https://doi.org/10.1007/s00180-016-0654-6.
- Shan, G., Chen, J. J., Ma, C. ( 2016a). Boundary problem in Simon's two-stage clinical trial designs. Journal of Biopharmaceutical Statistics null doi:10.1080/10543406.2016.1148716. URL https://doi.org/10.1080/10543406.2016.1148716.
- Shan, G. and Ma, C. ( 2016). Unconditional tests for comparing two ordered multinomials. Statistical Methods in Medical Research 25(1):241–254, doi:10.1177/0962280212450957. URL https://doi.org/10.1177/0962280212450957.
- Shan, G., Ma, C., Hutson, A. D., Wilding, G. E. ( 2013). Randomized Two-Stage Phase II Clinical Trial Designs Based on Barnard's Exact Test. Journal of Biopharmaceutical Statistics 23(5):1081–1090, doi:10.1080/10543406.2013.813525. URL https://doi.org/10.1080/10543406.2013.813525.
- Shan, G., Moonie, S., Shen, J. ( 2016b). Sample size calculation based on efficient unconditional tests for clinical trials with historical controls. Journal of Biopharmaceutical Statistics 26(2):240–249. URL http://view.ncbi.nlm.nih.gov/pubmed/25551261.
- Shan, G., Wang, W. ( 2013). ExactCIdiff: An R Package for Computing Exact Confidence Intervals for the Difference of Two Proportions. The R Journal 5(2):62–71.
- Shan, G., Wilding, G. E., Hutson, A. D., Gerstenberger, S. ( 2016c). Optimal adaptive two-stage designs for early phase II clinical trials. Statistics in Medicine 35(8):1257–1266, doi:10.1002/sim.6794. URL https://doi.org/10.1002/sim.6794.
- Shan, G., Zhang, H. ( 2016). Exact unconditional sample size determination for paired binary data (letter commenting: J Clin Epidemiol. 2015;68:733–739.). Journal of Clinical Epidemiology in press. Available at: https://doi.org/10.1016/j.jclinepi.2016.07.018.
- Shan, G., Zhang, H., Jiang, T. ( 2016d). Minimax and admissible adaptive two-stage designs in phase II clinical trials. BMC Medical Research Methodology 16(1):90, doi:10.1186/s12874-016-0194-3. URL https://doi.org/10.1186/s12874-016-0194-3.
- Shan, G., Zhang, H., Jiang, T., Peterson, H., Young, D., Ma, C. ( 2016e). Exact p-Values for Simon's Two-Stage Designs in Clinical Trials. 8(2):351–357, doi:10.1007/s12561-016-9152-1. URL https://doi.org/10.1007/s12561-016-9152-1.
- Simon, R. ( 1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10(1):1–10. URL http://view.ncbi.nlm.nih.gov/pubmed/2702835.
- Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. ( 2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92(3):205–216. URL https://doi.org/10.1093/jnci/92.3.205.
- Wang, W. ( 2010). On construction of the smallest one-sided confidence interval for the difference of two proportions. The Annals of Statistics 38(2):1227–1243, doi:10.1214/09-aos744. URL https://doi.org/10.1214/09-aos744.
- Whitehead, J. ( 1986). On the bias of maximum likelihood estimation following a sequential test. Biometrika 73(3):573–581, doi:10.1093/biomet/73.3.573. URL https://doi.org/10.1093/biomet/73.3.573.
- Wolsey, L. A. ( 1998). Integer Programming. 1st ed. New York: Wiley-Interscience. URL http://www.worldcat.org/isbn/0471283665.
- Wu, Y., Shih, W. J. ( 2008). Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design. Statistics in Medicine 27(29):6190–6208, doi:10.1002/sim.3426. URL https://doi.org/10.1002/sim.3426.
- Zeng, D., Gao, F., Hu, K., Jia, C., Ibrahim, J. G. ( 2015). Hypothesis testing for two-stage designs with over or under enrollment. Statistics in Medicine 34(16):2417--2426.